Marianne Dicander Alexandersson

Investor in Life Science companies

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO"​).

West Atlantic was created in 2011 through the merger of two of Europe’s most established independent cargo airlines, West Air Europe of Sweden and Atlantic Airlines of the UK. Now based in Malmö, the merged entity is also Europe’s largest cargo airline and most experienced provider of unique, integrated Ground to Air logistics for the Mail industry. Pioneering the technical competence necessary to move existing Mail trolleys directly from the truck to the aircraft has been a key factor in improving efficiency and service quality where employed in Scandinavia. West Atlantic are providers of complete turnkey cargo aircraft solutions, have an annual turnover in excess of €100 million and employ some 450 staff to operate a fleet in excess of 50 aircraft.

Enzymatica is a life science company whose business concept is to offer effective aid against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for common colds, ColdZyme® and launched it on four markets. The product became the leading article for common cold in Swedish pharmacies during winter 2014-2015. For product inf, please visit at www.coldzyme.co.uk. The development program includes medical devices in upper respiratory infections and oral health, and veterinary products.

We are a progressive and human-centric MedTech company specialising in innovative solutions for wound care and surgical procedures. Our products and solutions are trusted by hospitals, health care providers and patients in over 100 countries worldwide.

Investor in Life Science companies

Saminvest är ett riskkapitalbolag, bildat av staten 2016. Saminvest arbetar aktivt för etableringen av nya venture capital-fonder (”VC”) med tillräckliga kvaliteter och långsiktighet att kunna utveckla den svenska riskkapitalmarknaden. Detta för att flera innovativa och snabbväxande företag ska få tillgång till såväl kapital som ägarkompetens. Totalt förvaltar Saminvest tillgångar på cirka sex miljarder kronor.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical Phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on the Nasdaq First North Growth Market (ticker "PROMO"​).

Praktikertjänst är den största koncernen inom privat tandvård och hälso- och sjukvård i Sverige. Affärsmodellen är unik med 2 000 aktieägare som själva är verksamhetsansvariga på mottagningarna. Aktieägarna är tandläkare, tandtekniker, tandhygienister, läkare, sjukgymnaster/fysioterapruter, psykoanalytiker/terapeuter, psykologer, sjuksköterskor, barnmorskor, logopeder, arbetsterapeuter, socionomer, kiropraktorer och dietister. Den verksamhetsansvariga leder mottagningen och är entreprenören med ansvar för driften av mottagningen. Det omfattar det odontologiska och medicinska ansvaret, samt ansvaret för ekonomi, medarbetare och verksamhetsutveckling. Praktikertjänst AB är vårdgivare. Administration, rådgivning med mera sköts i stor utsträckning centralt vid huvudkontoret i Stockholm. Praktikertjänst omsätter cirka 9 miljarder kronor och sysselsätter cirka 8 783 medarbetare. I koncernen ingår även femton dotterbolag. In English Praktikertjänst is the largest private dental and health care group in Sweden. The business model is unique - the 2,000 shareholders are themselves practitioners who provide dental and medical care at clinics throughout the country. In 2013, the revenues amounted to SEK 9,600 M and the number of employees were 8,783. Within the Praktikertjänst Group, there are also 15 subsidiaries. Bättre vård för bättre liv ▪ Better care for a better life ▪ www.praktikertjanst.se ▪ Tfn växel huvudkontor 010-128 00 00 ▪ Facebook.com/praktikertjanst ▪ Twitter.com/praktikertjanst

Sahlgrenska Science Park is a community for the Life Science sector focusing on innovation and business acceleration. Well-connected and with a non-profit approach, we provide companies with tailored advice and support to catalyze ideas for a better, healthier world. Bringing together the resources from the industry, academia, healthcare and government, we offer an ecosystem for innovators and businesses to collaborate and grow. Our goal is to establish West Sweden as a recognized world class life science region with sustainable and competitive companies.